Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2010-04-06 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Report from LCTs Russian Phase I / IIa Diabetes Trial 5 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement providing detailed results and analysis from a clinical trial (Phase I/IIa) of a diabetes treatment product, DIABECELL®. It includes safety and efficacy data, patient follow-up information, and trial design details. The document is not a financial report, earnings release, or regulatory filing related to financial performance. It is a detailed update on clinical trial progress and results, which is typical of a company announcement or press release rather than a formal regulatory filing. There is no indication that this is an Annual Report, Interim Report, or any other financial or governance report. The document is lengthy (over 12,000 characters) and contains substantive data about the trial results, but it is not a financial or audit report. It is best classified as a Regulatory Filing (RNS) because it is a general company announcement about clinical trial results that does not fit into other specific categories such as earnings, management changes, or capital updates.
2010-04-06 English
LCT Phase II Diabetes Trial Success - Approval to Progress 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited regarding the progress and positive assessment of their Phase II Diabetes Trial. It discusses clinical trial results, approvals to proceed to the next trial phase, and future trial plans. The content is focused on clinical trial updates and company progress rather than financial results, regulatory filings, or shareholder information. It is not a financial report, earnings release, or regulatory filing. The document is an announcement of clinical trial progress and company news, which fits best under the category of a general regulatory announcement or company update. Given the absence of financial data or detailed report content, and the nature of the announcement, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other categories.
2010-03-29 English
Response to ASX Price Query 3 pages ?Kb
Regulatory Filings
2010-03-16 English
Russia registers LCT encapsulation delivery device 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about the registration of their encapsulation device in Russia. It discusses the commercial development and clinical trials of their products but does not contain any financial data, regulatory filings, or detailed financial reports. It is a news or corporate announcement about a product registration and commercial progress rather than a financial report, management change, or regulatory filing. The document length is 5727 characters, which is relatively short and focused on a specific announcement. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general company announcement, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2010-03-09 English
Half Yearly Report and Accounts 26 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4D' and is described as a 'Half yearly report' for the financial period ended 31 December 2009. It contains detailed financial data including revenue, profit/loss, dividends, net tangible asset backing, and a comprehensive Directors' Report. It also includes consolidated interim financial statements with various financial statements and notes. The document explicitly states it is an interim financial report for six months ended 31 December 2009 and includes substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR). The document is lengthy (15,000 characters) and contains actual financial statements, not just an announcement or summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is IR with high confidence. H1 2010
2010-02-24 English
LCT Awarded NZ$4.04 Million New Zealand Government Grant 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about being awarded a government grant to support development costs for their DIABECELL product. It discusses the grant amount, purpose, and company statements but does not contain any financial statements, detailed financial results, or regulatory filings. It is a funding update related to capital for development and commercialization activities. The document length is 6729 characters, which is sufficient for a substantive announcement. There is no indication that this is a full financial report, audit, or earnings release. The content fits best with a Capital/Financing Update (CAP) as it announces a significant government grant funding the company's development efforts.
2010-02-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.